⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
MRK News
Merck & Co., Inc.
MXene Industry Research Report 2026: Market to Grow at a CAGR of 35.6% to 2032, Driven by EV & Charging Infrastructure, Water Treatment Applications and High-Performance Aerospace & Defense Systems
globenewswire.com
MRK
AI in Pharma Manufacturing Market Research 2026-2040: Pfizer, Moderna, Novartis, Merck, and Sanofi are Integrating AI Into Their Operations As the Sector Evolves Towards Pharma 4.0
globenewswire.com
PFE
MRNA
NVS
MRK
SNY
COMPUTEX 2026 Brings the Global AI Ecosystem to Taipei
prnewswire.com
MSI
INTC
TXN
NVDA
AMAT
KLAC
LRCX
MU
QCOM
AMD
GOOG
MSFT
AMZN
IBM
DELL
HPQ
VRTX
ADI
NXPI
ON
MCHP
SNPS
CDNS
MRVL
ADSK
CTAS
PAYX
ADP
CRM
NOW
PANW
FTNT
ZBRA
HON
GE
ROK
ETN
GOOGL
META
NFLX
DIS
CMCSA
T
VZ
TMUS
CSCO
ORCL
SAP
ACN
DXC
WDC
SE
SMCI
DDOG
MDB
ZS
CRWD
SNOW
PLTR
UPST
COIN
PYPL
AFRM
SOFI
HOOD
UPWK
FIVN
RBLX
EA
TTWO
U
EXAS
REGN
BIIB
GILD
AMGN
BMY
PFE
MRK
JNJ
ABBV
LLY
NVO
AZN
XOM
CVX
SHEL
BABA
JD
PDD
NTES
BIDU
VIPS
EDU
BEKE
TAL
BILI
RLX
XPEV
NIO
LI
CPT
LCID
RIVN
TSLA
GM
F
STLA
VWAGY
HOG
YETI
GOOS
LULU
UA
NKE
ANF
AEO
URBN
PVH
RL
TJX
M
BBY
WMT
COST
TGT
HD
LOW
SPG
PLD
AMT
EQIX
CCI
DLR
SBAC
Global Implanted Brain-Computer Interface Devices Market to Observe Stupendous Growth at a CAGR of ~10% by 2032 | DelveInsight
prnewswire.com
LIVN
SNAP
GE
BSX
JNJ
PFE
MRK
BMY
LLY
NVO
PHG
Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
prnewswire.com
CMPX
MRK
PFE
BOLD
REPL
RDHL
RLAY
LLY
INCY
JAZZ
Living with a Rare Disease: A Pastor’s Journey Finding the Right Care and Treatment for NF1-PN
globenewswire.com
SWKS
MRK
Monoclonal Antibodies (mAbs) for Oncology Global Report 2026: A $228 Billion Market by 2030, Driven by Technological Advances, New Product Launches, Label Expansions, Increasing Prevalence
globenewswire.com
MRK
KEYTRUDA ® (pembrolizumab) Plus WELIREG ® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)
businesswire.com
MRK
WELIREG ® (belzutifan) Plus LENVIMA ® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
businesswire.com
MRK
A Symbol of Crisis: As Colorectal Cancer Deaths Rise, Fight CRC Installs United in Blue on the National Mall
globenewswire.com
AMGN
BMY
EXEL
EXAS
GENK
GSK
JNJ
MRK
NTRA
PFE